Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

This study tests a combination of tagraxofusp with low-intensity chemotherapy for adults with acute myeloid leukemia (AML) that has returned or stopped responding to the standard first-line treatment of venetoclax plus a hypomethylating agent. **You may be eligible if...** - You are 18 or older with AML that has relapsed or is no longer responding to treatment - Your AML cells express a protein called CD123 - Your initial treatment was venetoclax combined with azacitidine or decitabine (with or without a subsequent IDH or FLT3 inhibitor) - Your heart function (ejection fraction) is at least 50% - Your liver and kidney function are adequate **You may NOT be eligible if...** - You have received treatments other than those specified above - You have significant heart disease (such as heart failure or a recent heart attack) - You have HIV or active hepatitis B or C - You are currently receiving immunosuppressive therapy - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.